Regeneron (NASDAQ: REGN) reported Q3 EPS of $3.13, $0.40 better than the analyst estimate of $2.73. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.29 billion.

EYLEA sales rose 16% to $854 million, from $734 million in Q315.

2016 Financial Guidance(3)

The Company's updated full year 2016 financial guidance consists of the following components:

EYLEA U.S. net product sales	23% - 25% growth over 2015 (previously 20% - 25% growth over 2015)
Sanofi reimbursement of Regeneron commercialization-related expenses	$310 million - $335 million (previously $310 million - $340 million)
Non-GAAP unreimbursed R&D(2) (4)	$945 million - $975 million (previously $970 million - $1.01 billion)
Non-GAAP SG&A(2) (4)	$965 million - $995 million (previously $980 million - $1.02 billion)
Effective tax rate	29% - 33% (previously 33% - 41%)
Capital expenditures	$480 million - $510 million (previously $480 million - $530 million)

For earnings history and earnings-related data on Regeneron (REGN) click here.